Target #04Nasdaq: PFSADigital health / biosensorsUnited States
PFSA
Profusa, Inc.
$0.61710.21%USD · Nasdaq, delayed
// Intel
Key numbers
Market cap$373.7K
Volume218,869
52-week high$1,726
52-week low$0.5984
From 52w high-99.96%
Shares (implied)605,647
1% stake costs$3.7K
Rank#4 smallest of 10
// Profile
About Profusa
Berkeley company developing injectable, tissue-integrated biosensors: the Lumee Oxygen Platform (offered in the EU) and a months-long Lumee glucose monitor in R&D. Listed through its merger with NorthView Acquisition in July 2025.
Why it’s a target
More than a decade of implantable-sensor R&D, valued at about $0.37M on roughly 606k shares. A hard-tech platform this small needs a patient owner more than it needs another note.
Main risk
Funded by a run of convertible notes from August to October 2026, with $0.7M cash at June 30. It reverse-split 1-for-25 in July and 1-for-4 in August, and sought authority for up to 1-for-12 more.
// The ladderPFSA
- 1%Top holder$3.7KTop-holder list on most micro-caps
- 5%13D filed$18.7KSchedule 13D/13G beneficial-owner filing
- 10%Insider$37.4KSection 16 insider status
- 50.1%Control$187.2KMajority control of the vote
Costs at the last price, before market impact.
// In play